Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis
{{output}}
Takeda Pharmaceutical Co Ltd is developing dexlansoprazole, an oral controlled-release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis. By January 2008, an NDA for gastric acid-related diseases had been filed with the FDA,... ...
